跳至主要内容
临床试验/ACTRN12618001740280
ACTRN12618001740280尚未招募不适用

Drug hypersensitivity reactions to direct acting hepatitis C virus antiviral drugs

Prof Michaela Lucas0 个研究点目标入组 108 人开始时间: 2018年10月23日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
108

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Diagnosis of drug hypersensitivity reaction (HSR) confirmed using:
  • Modified European Network of Drug Allergy (ENDA) drug allergy questionnaire.
  • Severe Cutaneous Adverse Reactions (SCAR) to drugs criteria.
  • Idiosyncratic drug-induced liver injury (iDILI) criteria.
  • Clinical severity.
  • Direct acting antiviral drug treatment at time of hypersensitivity reaction.
  • Laboratory parameters: liver function test, total bilirubin.
  • Informed consent for health information acquisition, DNA bio-sample (buccal swab).

排除标准

  • People under the age of 18years.
  • Females that are pregnant.
  • Those people not willing to give consent.

研究者

发起方
Prof Michaela Lucas

相似试验

尚未招募
不适用
Drug hypersensitivity study using a diagnosis algorithm to examinations of a suspected adverse drug reactioIn this study, we investigate drug hypersensitivity using a definitive diagnosis algorithm (modified Mirakian R. Clin Exp Allergy. 2009 Jan39:43-61.) to examinations of a suspected adverse drug reaction.
JPRN-UMIN000026980Department of Pediatrics, Ehime University Hospital40
进行中(未招募)
不适用
In vitro evaluation of allergic reactions in hemophilia B subjects who have exhibited a systemic allergic response after exposure to BeneFIX (Nonacog Alfa; recombinant Factor IX) - Basophil Clinical StudyHemophilia B
EUCTR2004-002648-88-DEWyeth Pharmaceuticals18
进行中(未招募)
不适用
In vitro evaluation of allergic reactions in hemophilia B subjects who have exhibited a systemic allergic response after exposure to BeneFIX (Nonacog Alfa; recombinant Factor IX)
EUCTR2004-002648-88-FRWyeth Pharmaceuticals18
进行中(未招募)
1 期
In vitro evaluation of allergic reactions in hemophilia B subjects who have exhibited a systemic allergic response after exposure to BeneFIX (Nonacog Alfa; recombinant Factor IX) - Basophil Clinical StudyHemophilia B
EUCTR2004-002648-88-GBWyeth Pharmaceuticals18
已完成
不适用
Patient´s awareness of a direct adverse drug reaction reporting system: an exploratory survey conducted at the Medical Center - University of Freiburg.Report of adverse drug reactions by patients.
DRKS00007917niversitätsklinikum FreiburgStudienzentrum131